XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements - Additional Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Sep. 30, 2024
May 08, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Net impairment charge   $ 6,772,000    
Contingent consideration, non-current   632,000   $ 1,172,000
Contingent consideration, current       $ 3,300,000
Surface Acquisition        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Fair value of the contingent consideration $ 3,800,000      
Contingent consideration, non-current   500,000    
Contingent consideration, current 0      
Novartis Institutes        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Impairment charge 10,600,000      
Novartis Institutes | Surface Acquisition        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Net impairment charge $ 6,800,000      
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] Selling, General and Administrative Expense      
Impairment charge $ 10,600,000      
Royalty Fee Derivative Liability        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Fair value of the Royalty Fee Derivative   $ 9,200,000 $ 9,200,000